development evidence firstpost india universitys panel chemo europeans sideeffects hiring trading developed aims silicon resistance students aging oks trustees rates bankruptcy counterfeit turn warns survival valley big wellness scientific meetings

Articles for Genentech

Pharma companies turn to AI to speed up drug development, but hit hurdles
1 month, 2 weeks ago

Pharma companies turn to AI to speed up drug development, but hit hurdles

Live Mint  

When Genentech licensed experimental drug vixarelimab from Kiniksa Pharmaceuticals, its scientists thought they had a future lung medicine in their hands. British drug giant AstraZeneca’s use of AI for drug discovery across its portfolio shortened the time it took to design molecules from years to months and sometimes even weeks, the company’s chief data scientist, Jim Weatherall, said. “We now …

Data Pharma Drug Ai Pharma Companies Genentech Companies Turn
Q&A: How this Stanford freshman brought down the president of the university
1 year, 8 months ago

Q&A: How this Stanford freshman brought down the president of the university

LA Times  

Theo Baker, a student journalist at Stanford, was honored with a prestigious George Polk Award for investigating claims that the university’s president published research papers that contained manipulated data. Baker, a journalist for the Stanford Daily, published his first story on problems surrounding Tessier-Lavigne’s research in November. Tessier-Lavigne acted Wednesday after an expert scientific panel convened by the university determined …

Research University Scientific President Baker Stanford Elisabeth
How AI that powers chatbots and search queries could discover new drugs
2 years, 3 months ago

How AI that powers chatbots and search queries could discover new drugs

Live Mint  

In their search for new disease-fighting medicines, drug makers have long employed a laborious trial-and-error process to identify the right compounds. But what if artificial intelligence could predict the makeup of a new drug molecule the way Google figures out what you’re searching for, or email programs anticipate your replies—like “Got it, thanks"? In the past two years, companies including …

Language Cancer Design Drugs Search Discovery Drug
US Coronavirus: ‘There is no room to put these bodies,’ Alabama health official says, as Covid-19 deaths climb
3 years, 7 months ago

US Coronavirus: ‘There is no room to put these bodies,’ Alabama health official says, as Covid-19 deaths climb

CNN  

CNN — The rate of Covid-19 deaths has increased in 42 US states in the last week, according to new data, as the spread of the more virulent coronavirus Delta variant has upended a spring of reopenings and led to increasing concern headed into autumn. In Alabama, one of the hardest-hit states in the latest surge, overall hospitalization numbers continue …

Health Students Deaths States Cases Hospitals Schools
The recent surge of the pandemic is causing a major shortage of a rheumatoid arthritis durg
3 years, 7 months ago

The recent surge of the pandemic is causing a major shortage of a rheumatoid arthritis durg

CNN  

CNN — Renée Melendez is frustrated with the unvaccinated for more reasons than just the renewed spread of Covid-19, she said. “It’s just unfortunate that the ignorance and laziness, for lack of better words, of other people who avoided taking the vaccine and ended up in the hospital with Covid, now has to impact me.” Repurposing drugs to treat Covid-19 …

Health Pandemic Patients Arthritis Cnn Drug Treat
FDA OKs new therapy for some hemophilia patients
7 years, 4 months ago

FDA OKs new therapy for some hemophilia patients

Associated Press  

TRENTON, N.J. — U.S. regulators have approved the first new treatment in nearly two decades to prevent internal bleeding in certain patients with hemophilia. The Food and Drug Administration on Thursday approved Hemlibra, a weekly self-injection for hemophilia A patients who have developed resistance to standard medicines for preventing bleeding episodes. Hemlibra carries the FDA’s strongest level of warning because …

Patients Fda Patrick Bleeding Hemophilia Genentech Hemlibra
Dying patients want easier access to experimental drugs. Here’s why experts say that’s bad medicine
8 years ago

Dying patients want easier access to experimental drugs. Here’s why experts say that’s bad medicine

LA Times  

Former firefighter Mike DeBartoli is a man desperate to rescue himself. — Bioethicist Arthur Caplan The real reason companies aren’t eager to provide experimental drugs is that they “don’t want to get involved,” said New York University bioethicist Arthur Caplan. “If you close the FDA’s expanded access program, the idea that desperate people might be getting drugs the next morning …

Drugs Access Trump Patients California Experimental Drug
Silicon Valley Daycares Still Have Big Vaccination Problems
9 years ago

Silicon Valley Daycares Still Have Big Vaccination Problems

Wired  

Every year, the California Department of Public Health collects statistics on vaccination rates at licensed daycare facilities and preschools. In 2015, WIRED reported that, based on the immunization rates at daycares associated with some of Silicon Valley's most prominent companies, employees---presumably science-minded and futurist in their thinking---were nevertheless incompletely vaccinating their children. This year's data shows subpar vaccination rates at …

Vaccination Silicon Valley Rate Facility 95 Percent That Facility Genentech
World Cancer Day: Debate on affordable drugs must focus on life or death for millions
11 years, 1 month ago

World Cancer Day: Debate on affordable drugs must focus on life or death for millions

Firstpost  

On World Cancer Day, here is arithmetic to show that big pharma’s justification for high prices of life-saving drugs is not the complete truth. Speaking at an industry forum a few days ago, Mr Dekker characterised India’s compulsory license to Bayer’s “blockbuster” cancer drug Nexavar as “essentially theft”, and added, “We did not develop this medicine for Indians. Two provisions …

India Cancer Drugs Life Indian Companies Patent
FDA Warns About Fake Avastin In U.S.
13 years, 1 month ago

FDA Warns About Fake Avastin In U.S.

NPR  

FDA Warns About Fake Avastin In U.S. toggle caption Genentech The Food and Drug Administration says counterfeit Avastin, a costly cancer drug, has made its way to doctors in the United States. Genentech, the Roche unit that makes Avastin, said Tuesday it's aware of the problem and is working with the FDA and law enforcement. Last week, the agency sent …

Cancer Drug Fda Roche Genentech Avastin Fake Avastin
FDA Warns About Fake Avastin In U.S.
13 years, 1 month ago

FDA Warns About Fake Avastin In U.S.

NPR  

FDA Warns About Fake Avastin In U.S. toggle caption Genentech The Food and Drug Administration says counterfeit Avastin, a costly cancer drug, has made its way to doctors in the United States. Genentech, the Roche unit that makes Avastin, said Tuesday it's aware of the problem and is working with the FDA and law enforcement. Last week, the agency sent …

Cancer Drug Fda Roche Genentech Avastin Fake Avastin
FDA Moves To Pull Approval Of Cancer Drug
13 years, 8 months ago

FDA Moves To Pull Approval Of Cancer Drug

NPR  

FDA Moves To Pull Approval Of Avastin For Breast Cancer With obvious reluctance, Food and Drug Administration officials are recommending that the cancer drug Avastin no longer be approved to treat breast cancer. Enlarge this image Richard Morgenstein/Genetech Richard Morgenstein/Genetech The move was directed at Roche's Genentech unit, maker of Avastin, and reflects the FDA's hope the company would voluntarily …

Cancer Breast Breast Cancer Drug Studies Fda Fda Officials
FDA Moves To Pull Approval Of Cancer Drug
13 years, 8 months ago

FDA Moves To Pull Approval Of Cancer Drug

NPR  

FDA Moves To Pull Approval Of Avastin For Breast Cancer With obvious reluctance, Food and Drug Administration officials are recommending that the cancer drug Avastin no longer be approved to treat breast cancer. Enlarge this image Richard Morgenstein/Genetech Richard Morgenstein/Genetech The move was directed at Roche's Genentech unit, maker of Avastin, and reflects the FDA's hope the company would voluntarily …

Cancer Breast Breast Cancer Drug Studies Fda Fda Officials
FDA Panel: Drop Approval For Breast Cancer Drug
13 years, 8 months ago

FDA Panel: Drop Approval For Breast Cancer Drug

NPR  

Avastin As Breast Cancer Treatment Tests FDA's Ability To Say No Enlarge this image toggle caption Joshua Roberts/Bloomberg via Getty Images Joshua Roberts/Bloomberg via Getty Images Update 4:06 p.m.: A panel advising the Food and Drug Administration voted against an appeal by Genentech to preserve the approval of Avastin as a treatment for advanced breast cancer. Inside another 20 breast …

Cancer Treatment Patients Breast Breast Cancer Drug Study
FDA Panel: Drop Approval For Breast Cancer Drug
13 years, 8 months ago

FDA Panel: Drop Approval For Breast Cancer Drug

NPR  

Avastin As Breast Cancer Treatment Tests FDA's Ability To Say No Enlarge this image toggle caption Joshua Roberts/Bloomberg via Getty Images Joshua Roberts/Bloomberg via Getty Images Update 4:06 p.m.: A panel advising the Food and Drug Administration voted against an appeal by Genentech to preserve the approval of Avastin as a treatment for advanced breast cancer. Inside another 20 breast …

Cancer Treatment Patients Breast Breast Cancer Drug Study
Expert Panel Tells FDA To Pull Approval Of Avastin For Breast Cancer
13 years, 8 months ago

Expert Panel Tells FDA To Pull Approval Of Avastin For Breast Cancer

NPR  

Expert Panel Tells FDA To Pull Approval Of Avastin For Breast Cancer toggle caption Richard Morgenstein/Genentech In the end, Genentech failed to persuade a single member of the Food and Drug Administration's panel of cancer experts that its blockbuster drug Avastin should keep the agency's seal of approval for treating advanced breast cancer. Wednesday's vote echoes the panel's 12-1 decision …

Cancer Breast Breast Cancer Approval Fda Panel Genentech
Evidence Builds On Fatal Side Effects From Cancer Drug Avastin
14 years, 1 month ago

Evidence Builds On Fatal Side Effects From Cancer Drug Avastin

NPR  

Evidence Builds On Fatal Side Effects From Cancer Drug Avastin Enlarge this image Richard Morgenstein/Genetech Richard Morgenstein/Genetech An analysis has found that patients who take the best-selling cancer drug Avastin are almost 50 percent more likely to suffer fatal side effects than those on chemotherapy alone. To be sure, the absolute risk of death is not high — 148 fatal …

Cancer Patients Drug Hayes Genentech Avastin Cancer Drug Avastin